ESKLEROSI ANITZA
![Foto de ESKLEROSI ANITZA](/img/grupo.png)
![Foto de Hospital General Universitario de Alicante](/img/noimage_org.png)
Hospital General Universitario de Alicante
Alicante, EspañaHospital General Universitario de Alicante -ko ikertzaileekin lankidetzan egindako argitalpenak (11)
2024
-
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
Journal of neurology, Vol. 271, Núm. 1, pp. 472-485
2023
-
Comparative effectiveness in multiple sclerosis: A methodological comparison
Multiple Sclerosis Journal, Vol. 29, Núm. 3, pp. 326-332
-
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883
-
Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193
-
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011
-
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644
-
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis
European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024
2022
-
Confirmed disability progression as a marker of permanent disability in multiple sclerosis
European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334
-
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology
Multiple Sclerosis and Related Disorders, Vol. 63
2021
-
The age again in the eye of the COVID-19 storm: evidence-based decision making
Immunity and Ageing, Vol. 18, Núm. 1
2020
-
COVID-19: Age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study
Immunity and Ageing, Vol. 17, Núm. 1